Lexicon Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium

By: via Benzinga
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from the TELESTAR Phase 3 clinical study of telotristat etiprate ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.